NURS 5434 / NURS5434 CAD & Lipids Quiz – Family III (FNP... ~~$15.45~~ $13.95 Save 10% Add to Cart

3M+ Study Resources Risk-Free Purchase Instant Access

NURS 5434 / NURS5434 CAD & Lipids Quiz – Family III (FNP 3) 2026/ 2027 | UTA Latest Update | Practice Questions & Verified Answers

Name: NURS 5434 / NURS5434 CAD & Lipids Quiz – Family III (FNP 3) 2026/ 2027 | UTA Latest Update | Practice Questions & Verified Answers
Brand: Docmerit
SKU: DOC-2411602
Price: 13.95 USD
Availability: InStock
Author: Ogoma

Exam

NURS 5434 / NURS5434 CAD & Lipids Quiz – Family III (FNP 3) 2026/ 2027 | UTA Latest Update | Practice Questions & Verified Answers Q: Define the e ... [Show More] pidemiology of ASCVD with an emphasis on gender differences. Answer MEN: - leading cause of death; 1:4 - ETHNICITY: 1:13 white 1:14 black 1: 17 Hispanic - Half of men die suddenly of CAD had no previous symptoms Women - leading cause of death; 1:5 - ETHNICITY: leading cause of death for African American and white https://www.stuvia.com/user/quizbit07 - 1:16 20YR + have CAD (white, black, and Hispanic) - 1:30 asian - 64% of women died suddenly of CAD had no previous symptoms - ASCVD is more prevalent in men than women, with men having a higher incidence of coronary heart disease (CHD) and stroke. - However, women with ASCVD have higher mortality rates than men, and they also tend to develop ASCVD at an older age than men. (Hormonal factors, such as estrogen, may play a role in this gender difference.) Q: WHAT IS ASCVD Answer atherosclerotic cardiovascular disease - buildup of plaque in the arteries; can cause heart attack and stroke https://www.stuvia.com/user/quizbit07 Q: Describe the role of inflammation in the development of ASCVD. Answer A plaque is unstable due to inflammation. Statins stabilize and harden plaques, especially the lesion shoulders - interventions to decrease inflammation: include aspirin, smoking cessation, exercise, MUFAs - Chronic inflammation leads to the activation of immune cells -> cause damage to arterial walls & formation of atherosclerotic plaques. - Inflammation markers: high-sensitivity C-reactive protein (hs-CRP); used as a predictor of ASCVD risk. - anti-inflammatory drugs: canakinumab (reduce risk of recurrent cardiovascular events) - statins and PCSK9 inhibitors: anti-inflammatory effects; (targeting inflammation may be an effective strategy for preventing and treating ASCVD) Q: Identify the modifiable and non-modifiable risk factors for ASCVD; know male and female ages for premature CVD vs increased risk status based on age Modifiable risk factors: Answer - Dyslipidemia (raised LDL, Low HDL, raised TGS) - Smoking - Htn https://www.stuvia.com/user/quizbit07 - DM - Obesity - Dietary factors - Thrombogenic factors - Sedentary lifestyle Non-modifiable: - Age: males over 45 and females over 55 - Sex - Family hx of premature CHD: Males less than 55 and females less than 65 - Definite MI or sudden death Q: Describe the effect of statins on vulnerable plaques. Answer - lower cholesterol levels and reduce the risk of ASCVD. - stabilize vulnerable plaques, which are more prone to rupture and cause heart attacks. - Statins can also reduce inflammation in the arterial walls - decrease LDL https://www.stuvia.com/user/quizbit07 (stabilize plaques by lowering inflammation, lowering lipid accumulation, and stimulating the formation of collagen and other extracellular matrix proteins) Q: Differentiate between directing therapy to "global risk for ASCVD" vs. "LDL targets". Answer Managing global CVD includes - HTN control - Tobacco cessation - Lifestyle: weight and exercise - Healthy diet - Stress management Global risk assessment risk factors to estimate risk of developing ASCVD: - age, sex, BP, cholesterol levels, smoking, and DM (Treatment recommendations based on estimated risk) LDL targets: - focus specifically on lowering LDL regardless of an individual's overall risk of ASCVD - LDL targets have been used in the past, current guidelines emphasize the use of global risk assessment to guide treatment decisions https://www.stuvia.com/user/quizbit07 Q: Describe the role of the non-statin drugs (Fibrates & Niacin) for lipid problem. (Gemfibrozil & Fenofibrate) Answer Fibrates: Gemfibrozil- Should NOT be initiated in statin users because it can affect statin pathways Fenofibrate- - Should not be used in patients with GFR less than 30 ml/min - May be considered for use in low or moderate intensity statin users if trig is greater than 500 or ASCVD reduction deemed beneficial - Not a replacement treatment for statins Q: Describe the role of the non-statin drugs (Fibrates & Niacin) for lipid problem. Answer used to treat lipid problems (high triglyceride levels and low HDL) https://www.stuvia.com/user/quizbit07 - Fibrates: activating receptor that incr breakdown of triglycerides and promotes production HDL; RISK- gallstones - Niacin: incr HDL & can lower LDL (less commonly used than statins, associated w/ side effects and overall benefit in reducing ASCVD risk has not been as well established); RISK- liver toxicity If unable to take statins or continue have lipid abnormalities while taking statins could benefit; adjunctive therapy Q: Describe the role of the non-statin drugs (FIBRATES & Niacin) for lipid problem. PCSK9 inhibitors Answer PCSK9 inhibitors: - Reduce degradation of hepatic LDL receptors so they lower LDL - Very expensive - Injectable sq every 2 weeks - Alirocumab and evolocumab - CV events nearly reduced by 50% https://www.stuvia.com/user/quizbit07 Q: Identify the major recommendations in the 2018 Cholesterol Guidelines tha [Show Less]

Preview 2 out of 18 pages